STRIDES PHARMA SCIENCE LIMITED — Capital/Financing Update 2025

Mar 19, 2025

==> picture [96 x 40] intentionally omitted <==

March 19, 2025

The National Stock Exchange of India Limited Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai - 400 051. Scrip Code: STAR

The BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. Scrip Code: 532531

Dear Madam/ Sir,

Sub: Update regarding intimation of March 14, 2025 relating to Amexel

This has reference to Strides’ intimation of March 14, 2025 relating to acquisition of 100% stake in Amexel Pte. Ltd., Singapore (Amexel) by Strides Pharma Global Pte. Limited, Singapore, a Step-down Wholly Owned Subsidiary of the Company.

With reference to the above, we would like to inform you that the said transaction has achieved closure and Amexel is a Step-down Wholly owned Subsidiary of the Company effective March 19, 2025.

This is for your kind information and record purpose.

Thanks & Regards, For Strides Pharma Science Limited,

MANJUL Digitally signed by MANJULA R A R Date: 2025.03.19 17:08:38 +05'30' Manjula Ramamurthy Company Secretary ICSI Membership No. A30515

Strides Pharma Science Limited

CIN: L24230MH1990PLC057062 Corp. Off: Strides House, Bilekahalli, Bannerghatta Road, Bengaluru - 560 076, India Tel: +91-80-6784 0000 Fax: +91 80 6784 0700 Regd Off: ‘ Cyber One’, Unit No. 902, Plot No. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400 703, India Tel: +91-22-2789 2924/ 3199 corpcomm@strides.com; www.strides.com